Page 21 - Demo

ANALESRANFwww.analesranf.com34. Bernal S, Pelaez I, Alias L, et al. High MutationalHeterogeneity, and New Mutations in the HumanCoagulation Factor V Gene. Future Perspectivesfor Factor V Deficiency Using Recombinant andAdvanced Therapies. Int J Mol Sci 2021; 22(18):9705; doi:https://doi.org/10.3390/ijms22189705.35. De Pablo-Moreno JA, Liras A, Revuelta L.Standardization of Coagulation Factor VReference Intervals, Prothrombin Time, andActivated Partial Thromboplastin Time in Mice forUse in Factor V Deficiency Pathological Models.Front Vet Sci 2022; 9: 846216; doi:https://doi.org/10.3389/fvets.2022.846216.36. Serrano LJ, Garcia-Arranz M, De Pablo-Moreno JA,et al. Development and Characterization of aFactor V-Deficient CRISPR Cell Model for theCorrection of Mutations. Int J Mol Sci 2022;23(10): 5802; doi:https://doi.org/10.3390/ijms23105802.37. Patente %u201cM%u00e9todo in vitro para recuperar laexpresi%u00f3n del gen F5 que codifica el factor V dela coagulaci%u00f3n%u201d. Ref. ES2785323B2. Titulares:Universidad Complutense de Madrid y Fundaci%u00f3Institut de Recerca de L%u2019hospital de La Santa CreuI Sant Pau. Inventores: Liras Mart%u00edn, Antonio;Serrano Ramos, Luis Javier; Bernal Noguera,Sara. Bolet%u00edn Oficial de la Propiedad Industrial(18-12-2020) Vol. 2: Invenciones. p. 9. Disponibleen:https://consultas2.oepm.es/pdf/ES/0000/000/02/78/53/ES-2785323_B2.pdf.38. Patente %u201cMouse model, deficient in factor V%u201d. Ref.ES2948817B2. Titulares: UniversidadComplutense de Madrid y Consejo Superior deInvestigaciones Cient%u00edficas. Inventores: LirasMart%u00edn, Antonio; De Pablo Moreno, Juan Andr%u00e9s;Revuelta Rueda, Luis; Miguel Batuecas, Andrea;Bermejo Alvarez, Pablo y Gonz%u00e1lez Brusi,Leopoldo. Bolet%u00edn Oficial de la PropiedadIndustrial (21-02-2024) Vol. 2: Invenciones. p. 8.Disponible en:https://consultas2.oepm.es/pdf/ES/0000/000/02/94/88/ES-2948817_B2.pdf.39. La falta de impulso a los biosimilares impide elahorro de 431 millones de gasto farmac%u00e9utico enEspa%u00f1a. Diario P%u00fablico (sep 2023). Disponible en:https://www.publico.es/sociedad/falta-impulsobiosimilares-impide-ahorro-431-millones-gasto-farmaceutico-espana.html.22. Hu T, Chitnis N, Monos D, Dinh A. Next-generationsequencing technologies: An overview. HumImmunol 2021; 82(11): 801-11; doi:https://doi.org/10.1016/j.humimm.2021.02.01223. Blair HA. Valoctocogene Roxaparvovec: FirstApproval. Drugs 2022; 82(14): 1505-1510; doi:https://doi.org/10.1007/s40265-022-01788-y.24. Heo YA. Etranacogene Dezaparvovec: FirstApproval. Drugs 2023; 83(4): 347-352; doi:https://doi.org/10.1007/s40265-023-01845-0.25. Merlin S, Akula S, Cottonaro A, et al. Therapeuticpotential of fetal liver cell transplantation inhemophilia A mice. Haematologica 2023; 108(6):1544-54; doi:https://doi.org/10.3324/haematol.2022.282001.26. Serrano LJ, Ca%u00f1ete A, Garcia-Leal T, et al. Searchingfor a Cell-Based Therapeutic Tool for HaemophiliaA within the Embryonic/Foetal Liver and theAorta-Gonads-Mesonephros Region. ThrombHaemost 2018; 118(8): 1370-81; doi:https://doi.org/10.1055/s-0038-1661351.27. Lek A, Wong B, Allison Keeler A, et al. Death afterHigh-Dose rAAV9 Gene Therapy in a Patient withDuchenne%u2019s Muscular Dystrophy. N Engl J Med2023; 389(13): 1203-10; doi:https://doi.org/10.1056/NEJMoa2307798.28. von Drygalski A, Bhat V, Gale AJ, et al. Anengineered factor Va prevents bleeding inducedby anticoagulant wt activated protein C. PLoSOne 2014; 9(8): e104304; doi:https://doi.org/10.1371/journal.pone.0104304.29. Gale AJ, Bhat V, Pellequer JL, et al. Safety, Stabilityand Pharmacokinetic Properties of (super)FactorVa, a Novel Engineered Coagulation Factor V forTreatment of Severe Bleeding. Pharm Res 2016;33(6): 1517-26; doi:https://doi.org/10.1007/s11095-016-1895-3.30. Joseph BC, Miyazawa BY, Esmon CT, et al. Anengineered activated factor V for the preventionand treatment of acute traumatic coagulopathyand bleeding in mice. Blood Adv 2022; 6(3): 959-69; doi:https://doi.org/10.1182/bloodadvances.2021005257.31. Olmedillas S, Garcia-Arranz M, Garcia-Olmo D, LirasA. Preliminary study on non-viral transfection ofF9 (factor IX) gene by nucleofection in humanadipose-derived mesenchymal stem cells. PeerJ2016: 4: e1907; doi:https://doi.org/10.7717/peerj.1907.32. Biesert L, Suhartono H. Solvent/detergenttreatment of human plasma%u2014a very robustmethod for virus inactivation. Validated virussafety of OCTAPLAS. Vox Sang 1998; 74 (Suppl 1):207-12; doi: https://doi.org/10.1111/j.1423-0410.1998.tb05474.x.33. Serrano LJ, de la Torre P, Liras A, Flores AI. Celltherapy for factor V deficiency: An approachbased on human decidua mesenchymal stemcells. Biomed Pharmacother 2021; 142: 112059;doi:https://doi.org/10.1016/j.biopha.2021.112059.La magia de la Farmacobiotecnolog%u00eda: De las magistrales a los virus recombinantes en terapia g%u00e9nicaAntonio Liras Mart%u00edn 311 An. R. Acad. Farm.Vol. 90. n%u00ba 3 (2024) %u00b7 pp. 299-311Si desea citar nuestro art%u00edculo:La magia de la Farmacobiotecnolog%u00eda: De las magistrales a los virus recombinantes en terapia g%u00e9nicaAntonio Liras Mart%u00edn An Real Acad Farm (Internet).An. Real Acad. Farm.Vol. 90. n%u00ba 3 (2024) %u00b7 pp. 299-311 DOI:http://dx.doi.org/10.53519/analesranf.2023.90.03.01